https://www.businesswire.com/news/home/20221026005180/en/New-Analysis-of-UPLIZNA%C2%AE-inebilizumab-cdon-Phase-3-Trial-Data-Demonstrates-Importance-of-Reducing-Plasmablasts-to-Help-Prevent-Neuromyelitis-Optica-Spectrum-Disorder-NMOSD-Attacks
0
0
10/26/22 at 12:00pm
Organization
Business Wire
Authors
Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data from two analyses of the UPLIZNA Phase 3 pivotal trial being presented at the 38th Co
Create an account
or login to join the discussion